requirements to be fully enforced in 2019, as well. These new standards may eventually affect provisioning expenses, risk calculation and capital maintenance of commercial banks. All of these factors may change
. Clause 21 In the case where the licensee, being required to maintain its status of legal entity in a conglomerate pursuant to Clause 13(5), is to change its shareholding structure to the extent that it is
application. Clause 21 In the case where the licensee, being required to maintain its status of legal entity in a conglomerate pursuant to Clause 13(5), is to change its shareholding structure to the extent
- 2020 Balance by Quarter Change Q2–20 Q1–20 Q2–19 Q2–20 VS Q1–20 Q2–20 VS Q2–19 (Million Baht: MB) (MB) % (MB) % Total Revenue 1,187.6 1,231.7 1,729.6 (44.1) (3.6) (542.0) (31.3) Total Operating Expenses
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales
Q3–2020 Balance by Quarter Change Q3–20 Q2–20 Q3–19 Q3–20 VS Q2–20 Q3–20 VS Q3–19 (Million Baht: MB) (MB) % (MB) % Total Revenue 2,241.1 1,187.6 1,798.9 1,053.5 88.7 442.2 24.6 Total Operating Expenses
Three Months period ended 31 December (3M YoY) Sales by geography Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 31 December 2018 2019 THB mm % THB mm % THB mm